Short answer
Xenon Pharmaceuticals Inc. (XENE) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$111M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$111M
- −30.7% YoY · −8.2% QoQ
- EPS (diluted)
- −$1.11
- −3.7% YoY · +5.1% QoQ
Source: XBRL data from the Xenon Pharmaceuticals Inc. (XENE) Q2 2026 10-Q on SEC EDGAR. USD.
Xenon Pharmaceuticals Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly triggered risk identified; filing does not compare changes with the prior 10-K
- Phase 3 execution risk for azetukalner, with no prior experience completing Phase 3 studies or filing an NDA
- Regulatory compliance exposure from misconduct, including inaccurate clinical data, healthcare fraud, kickbacks, and privacy violations
- Competitive risk from safer, more effective, convenient, or lower-priced anti-seizure and antidepressant therapies
- Funding risk despite cash runway of at least 12 months, with net losses of $213.0 million for the six months ended June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xenon Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.